Adamas Pharmaceuticals expects net sales of Gocovri to be about $13.3M for Q4
Adamas Pharmaceuticals outlined key business priorities for 2019 and provided preliminary 2018 sales results for Gocovri extended release capsules. Gocovri is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population. Based on preliminary unaudited financial information, the company expects net sales of Gocovri to be approximately $13.3M for Q4 that ended December 31, 2018. During Q4, Adamas fulfilled approximately 5,700 paid prescriptions of Gocovri. Preliminary full-year unaudited net sales of Gocovri are expected to be approximately $34M, with approximately 15,500 paid prescriptions filled. Adamas ended the year with approximately $211M of cash, cash equivalents, and available-for-sale securities. Key priorities for 2019 include driving adoption and clinical conviction through commercial execution and focused education about the innovation and unique benefits of Gocovri; continue to maintain excellent persistence and durable use through positive patient experience; target an approximate doubling of total prescriptions for 2019 over 2018; advance the medical literature regarding Gocovri in the Parkinson's disease treatment journey and time dependent mechanisms of disease and action by continuing to publish data at major scientific and medical meetings; completion of enrollment for the Phase 3 INROADS study of ADS-5102 extended release capsules for multiple sclerosis walking impairment in the first half of 2019 and release top-line data in the second half of 2019; continue to advance ADS-4101 towards registration studies.